Pharmacokinetic study of XXXX in intraoperative hyperthermic i.p. chemotherapy for @entity43 .

@entity43 @entity1 @entity137 @entity5 @entity204 @entity1205 @entity298
The purpose of this study was to evaluate the pharmacokinetics and @entity137 of @entity1205 in @entity298 ( @entity298 ) after cytoreductive surgery for peritoneal involvement of gynecological @entity5 , mainly @entity43 . Eighteen @entity1 , with a mean age of 64 years (range 51-80), underwent cytoreductive surgery and subsequent @entity298 with 75 mg/m2 @entity1205 at 41-43 degrees C. One @entity1 was treated twice. In eight cases, peritoneal fluid and blood samples were obtained for pharmacokinetic analysis. @entity204 occurred in two heavily pretreated elderly @entity1 with a high volume i.p. @entity5 recurrence, probably reflecting poor @entity1 selection (mortality rate 10.5%). Other complications, mainly minor, were recorded after 63% of the procedures. Hematological @entity1205 -induced @entity137 was limited, while the incidence of wound complications was relatively high and probably caused by the direct exposure of the wound to @entity1205 during @entity298 . The maximal i.p. versus plasma concentration ratio ranged from 17 to 95 (average 45), while the i.p. versus systemic exposure ratio varied between 105 and 555 (average 207). We conclude that the use of @entity1205 in @entity298 following cytoreductive surgery seems feasible and results in a high i.p. versus systemic exposure ratio. The AUC for the peritoneal cavity is on average 13-27 times higher after i.p. administration of 75 mg/m2 during @entity298 than the AUC achieved in the systemic compartment after i.v. administration of the recommended dose of 100 mg/m2, while @entity1205 -induced systemic @entity137 is highly limited.
